| 000 | 01025 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250511181016.0 | ||
| 264 | 0 | _c19920203 | |
| 008 | 199202s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/0140-6736(92)91050-i _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBowen, D M | |
| 245 | 0 | 0 |
_aTreatment strategies for Alzheimer's disease. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJan 1992 |
||
| 300 |
_a132-3 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aCycloserine _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aReceptors, Neurotransmitter _xdrug effects |
| 650 | 0 | 4 |
_aSerotonin Antagonists _xtherapeutic use |
| 700 | 1 | _aFrancis, P T | |
| 700 | 1 | _aPangalos, M N | |
| 700 | 1 | _aStephens, P H | |
| 700 | 1 | _aProcter, A W | |
| 773 | 0 |
_tLancet (London, England) _gvol. 339 _gno. 8785 _gp. 132-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0140-6736(92)91050-i _zAvailable from publisher's website |
| 999 |
_c1352366 _d1352366 |
||